← All trials
NCT07059000
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2025
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Jul 10, 2025
- Last posted
- Nov 14, 2025
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kedrion SpALead sponsor
- ICONCollaborator
- Kedrion SpAOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.